NO963130L - Preparat for behandling av glaukom, omfattende pilokarpin og en betablokker - Google Patents

Preparat for behandling av glaukom, omfattende pilokarpin og en betablokker

Info

Publication number
NO963130L
NO963130L NO963130A NO963130A NO963130L NO 963130 L NO963130 L NO 963130L NO 963130 A NO963130 A NO 963130A NO 963130 A NO963130 A NO 963130A NO 963130 L NO963130 L NO 963130L
Authority
NO
Norway
Prior art keywords
glaucoma
blocker
beta
preparation
treatment
Prior art date
Application number
NO963130A
Other languages
English (en)
Other versions
NO963130D0 (no
Inventor
Yusuf Ali
Rajni Jani
George R Mccarty
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of NO963130L publication Critical patent/NO963130L/no
Publication of NO963130D0 publication Critical patent/NO963130D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparater for kontroll av glaukom og okular hypertensjon er be- skrevet. Disse preparatene omfatter pilokarpin, en slik betablokker som betaxolol, en ionebytterharpiks og en slik fleranionisk polymer som karbo- merer.
NO963130A 1994-01-28 1996-07-26 Preparat for behandling av glaukom, omfattende pilokarpin og en betablokker NO963130D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18828494A 1994-01-28 1994-01-28
US08/334,512 US5554367A (en) 1984-10-31 1994-11-04 Compositions for treatment of glaucoma
PCT/US1995/001017 WO1995020378A1 (en) 1994-01-28 1995-01-24 Compositions for treatment of glaucoma comprising pilocarpine and a beta-blocker

Publications (2)

Publication Number Publication Date
NO963130L true NO963130L (no) 1996-07-26
NO963130D0 NO963130D0 (no) 1996-07-26

Family

ID=26883909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963130A NO963130D0 (no) 1994-01-28 1996-07-26 Preparat for behandling av glaukom, omfattende pilokarpin og en betablokker

Country Status (9)

Country Link
US (1) US5554367A (no)
EP (1) EP0741563A1 (no)
JP (1) JP2854418B2 (no)
AU (1) AU688854B2 (no)
CA (1) CA2181929C (no)
FI (1) FI962976A0 (no)
MX (1) MX9603060A (no)
NO (1) NO963130D0 (no)
WO (1) WO1995020378A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
CN1124842C (zh) * 1997-11-05 2003-10-22 千寿制药株式会社 缓释滴眼剂
JP2002528423A (ja) * 1998-10-27 2002-09-03 アルコン ラボラトリーズ， インコーポレイテッド 局所投与可能な薬学的組成物のための保存系
DK1244438T3 (da) * 1999-11-30 2004-02-23 Alcon Inc Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050106321A1 (en) * 2003-11-14 2005-05-19 Molecular Imprints, Inc. Dispense geometery to achieve high-speed filling and throughput
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法
US9918970B2 (en) * 2010-05-19 2018-03-20 Astellas Pharma Inc. Pharmaceutical composition comprising solifenacin
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4342783A (en) * 1980-06-30 1982-08-03 Synthelabo Anti-glaucoma agent
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions

Also Published As

Publication number Publication date
JPH09505604A (ja) 1997-06-03
AU1607495A (en) 1995-08-15
JP2854418B2 (ja) 1999-02-03
CA2181929A1 (en) 1995-08-03
EP0741563A1 (en) 1996-11-13
WO1995020378A1 (en) 1995-08-03
AU688854B2 (en) 1998-03-19
CA2181929C (en) 1998-11-03
FI962976A (fi) 1996-07-26
US5554367A (en) 1996-09-10
NO963130D0 (no) 1996-07-26
MX9603060A (es) 1997-03-29
FI962976A0 (fi) 1996-07-26

Similar Documents

Publication Publication Date Title
NO963130L (no) Preparat for behandling av glaukom, omfattende pilokarpin og en betablokker
AU4024689A (en) Substituted 4-azatricyclo (22.3.1.0 4,9) octacos-18-ene derivatives
NO975702D0 (no) Fremgansmåte for fremstilling av lavmolekylært, höyreaktivt polyisobuten
AU1808595A (en) 3,8-diazabicyclo{3.2.1}octane derivatives having analgesic activity
EP0609061A3 (en) Curable composition, polymer, organic glass and ophthalmic lens.
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
EP0396394A3 (en) Sterilisable lubricant
AU8321791A (en) Oligosaccharide mixture, and procedure for its manufacturing
AU4330796A (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz(b,f)oxepines
AU641279B2 (en) Oligosaccharide derivatives
FI915492A0 (fi) 9a-hydroxi-19,11b-oeverbryggade steroider, deras framstaellning och farmaceutiska preparat som innehaoller dem.
DE68900210D1 (de) Pyranobenzoxadiazolderivate, herstellung, verwendung und diese enthaltende zubereitungen.
NO891046D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2,4-triazol-derivater.
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
NO893784L (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktiveimidazolderivater.
NO893768D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2,7-diamino-1,2,3,4-tetrahydronaftalenderivater.
NO891025L (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktivesialosylglycerider.
AU3406089A (en) Novel strobilurine derivatives, their preparation and their use
RU1825995C (ru) Устройство дл измерени давлени
BR9901387A (pt) Composições para a cura de polìmero.
AU3776789A (en) Monomers, oligomers, and polymers of biscyclobutarenes bridged by at least one benzoxazole, benzothiazole or benzimidazole linkage
DE3878988T2 (de) 1,2-Di(4-isobutylphenyl)äthylen, dessen Herstellung und Verwendung als Zwischenprodukt.
NO931560D0 (no) 4- eller 5-(sulf)imido- og (sulfon)amidoyridiner saavel som deres pyridin-n-oksyder, fremgangsmaater for fremstillingav dem og deres anvendelse som legemiddel
RU1808895C (ru) Напорна сортировка
AU2505597A (en) Ribose-5-phosphate isomerase (d-ribose-5-phosphate ketol isomerase, ec 5.3.1.6)